Adaptimmune Therapeutics 향후 성장

Future 기준 점검 2/6

Adaptimmune Therapeutics은 연간 수입과 매출이 각각 61.8%와 39.9% 증가할 것으로 예상되고 EPS는 연간 64.3%만큼 증가할 것으로 예상됩니다.

핵심 정보

61.8%

이익 성장률

64.31%

EPS 성장률

Biotechs 이익 성장	23.4%
매출 성장률	39.9%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	28 Oct 2025

최근 향후 성장 업데이트

Recent updates

TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies

Apr 04 Rapid treatment network expansion and successful TECELRA launch are driving significant future revenue growth and patient access.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Mar 11

Investors Don't See Light At End Of Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Tunnel And Push Stock Down 26%

Jan 01

Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?

Dec 15

Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

Nov 15

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Apr 16

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Feb 22

Adaptimmune: Drug Approval Now Imminent?

Feb 02

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Nov 09

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Mar 08

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Feb 20

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

Sep 20

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Aug 10

Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

Aug 03

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Jun 29

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Jun 19

Adaptimmune Therapeutics: A Little More Patience May Be Profitable

Mar 06

이익 및 매출 성장 예측

OTCPK:ADAP.Y - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2027	153	-49	39	N/A	2
12/31/2026	78	-60	16	N/A	2
12/31/2025	53	-135	5	N/A	1
6/30/2025	65	-170	-193	-190	N/A
3/31/2025	180	-70	-111	-108	N/A
12/31/2024	178	-71	-76	-73	N/A
9/30/2024	175	-45	-56	-54	N/A
6/30/2024	141	-72	-47	-44	N/A
3/31/2024	18	-163	-138	-136	N/A
12/31/2023	60	-114	-146	-141	N/A
9/30/2023	71	-95	-132	-124	N/A
6/30/2023	71	-91	-145	-127	N/A
3/31/2023	71	-114	-150	-125	N/A
12/31/2022	27	-165	-172	-142	N/A
9/30/2022	18	-175	-40	-10	N/A
6/30/2022	12	-176	-29	-7	N/A
3/31/2022	9	-171	-12	3	N/A
12/31/2021	6	-158	2	11	N/A
9/30/2021	6	-156	-158	-152	N/A
6/30/2021	6	-149	-129	-124	N/A
3/31/2021	4	-140	-121	-117	N/A
12/31/2020	4	-130	-56	-54	N/A
9/30/2020	3	-123	-39	-37	N/A
6/30/2020	2	-127	-52	-50	N/A
3/31/2020	2	-138	-62	-59	N/A
12/31/2019	1	-137	-116	-113	N/A
9/30/2019	2	-144	-134	-132	N/A
6/30/2019	42	-99	-96	-92	N/A
3/31/2019	51	-102	N/A	-93	N/A
12/31/2018	60	-96	N/A	-104	N/A
9/30/2018	62	-87	N/A	-94	N/A
6/30/2018	49	-93	N/A	-91	N/A
3/31/2018	43	-69	N/A	-73	N/A
12/31/2017	38	-70	N/A	-54	N/A
9/30/2017	42	-58	N/A	-31	N/A
6/30/2017	17	-76	N/A	-59	N/A
3/31/2017	14	-78	N/A	-58	N/A
12/31/2016	14	-72	N/A	-48	N/A
9/30/2016	10	-73	N/A	-68	N/A
6/30/2016	12	-61	N/A	-53	N/A
3/31/2016	15	-55	N/A	-45	N/A
12/31/2015	14	-48	N/A	-32	N/A
9/30/2015	13	-19	N/A	-20	N/A
6/30/2015	10	-37	N/A	-30	N/A
3/31/2015	7	-16	N/A	-4	N/A
12/31/2014	4	-12	N/A	24	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ADAP.Y 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ADAP.Y 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ADAP.Y 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ADAP.Y 의 수익(연간 39.9%)이 US 시장(연간 10.5%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: ADAP.Y 의 수익(연간 39.9%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ADAP.Y의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/05 21:53
종가	2025/11/04 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Adaptimmune Therapeutics plc는 12명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Peter Lawson	Barclays
Ying Huang	BofA Global Research
Mohit Bansal	Citigroup Inc

Adaptimmune Therapeutics 향후 성장

Future 기준 점검 2/6

핵심 정보

최근 향후 성장 업데이트

Consensus EPS estimates fall by 23%, revenue upgraded

Price target decreased by 9.3% to US$2.21

Price target decreased by 11% to US$2.43

Consensus revenue estimates increase by 152%

Consensus revenue estimates increase by 25%

Price target increased by 9.6% to US$2.74

Recent updates

Adaptimmune Therapeutics plc(OTCPK:ADAP.Y) dropped from NASDAQ Composite Index

Nasdaq Grants Adaptimmune Therapeutics plc an Exception Period to Regain Compliance with Nasdaq Listing Rule 5550(a)(2)

Adaptimmune Therapeutics plc Receives Non-Compliance Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Adaptimmune Therapeutics Receives Notice of Potential Delisting from Nasdaq Regarding the Minimum Bid Price Requirement for its American Depositary Shares

Adaptimmune Therapeutics plc Enters into A Settlement and Release Agreement with the University of Texas M.D. Anderson Cancer Center

Adaptimmune Therapeutics plc to Report Q1, 2025 Results on May 13, 2025

Adaptimmune Therapeutics Receives ADS Listing Transfer Approval to Nasdaq Capital Market

Adaptimmune Therapeutics plc, Annual General Meeting, May 29, 2025

Adaptimmune Therapeutics plc Announces Termination Date of Gavin Wood, Chief Financial Officer, to Be August 31, 2025 by Reason of Redundancy

TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies

Consensus EPS estimates fall by 23%, revenue upgraded

Adaptimmune Therapeutics plc Auditor Raises 'Going Concern' Doubt

Full year 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Price target decreased by 9.3% to US$2.21

Adaptimmune Therapeutics plc to Report Q4, 2024 Results on Mar 20, 2025

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough

Investors Don't See Light At End Of Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Tunnel And Push Stock Down 26%

Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?

Price target decreased by 11% to US$2.43

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

Adaptimmune Therapeutics Receives Notice from the Nasdaq Regarding Not in Compliance with Listing Rule 5450(a)(1)

Adaptimmune Therapeutics plc to Report Q3, 2024 Results on Nov 13, 2024

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Consensus revenue estimates increase by 152%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Adaptimmune Therapeutics plc to Report Q2, 2024 Results on Aug 12, 2024

Consensus revenue estimates increase by 25%

Adaptimmune Therapeutics plc Receives U.S. FDA Accelerated Approval of TECELRA®

Price target increased by 9.6% to US$2.74

Consensus EPS estimates upgraded to US$0.44 loss

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Consensus EPS estimates fall by 19%

Consensus revenue estimates decrease by 59%, EPS upgraded

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Financial position

Consensus EPS estimates upgraded to US$0.25 loss, revenue downgraded

Adaptimmune Therapeutics plc to Report Q1, 2024 Results on May 15, 2024

Price target decreased by 7.1% to US$3.50

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Consensus EPS estimates fall by 11%

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Consensus estimates of losses per share improve by 21%

Adaptimmune Therapeutics plc, Annual General Meeting, May 14, 2024

New major risk - Shareholder dilution

Consensus revenue estimates increase by 56%

New major risk - Financial position

Adaptimmune Therapeutics plc Appoints Cintia Piccina as Chief Commercial Officer, Effective March 18, 2024

New major risk - Share price stability

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Adaptimmune Therapeutics plc to Report Q4, 2023 Results on Mar 06, 2024

Adaptimmune Therapeutics Regains Nasdaq Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5450(a)(1)

Adaptimmune: Drug Approval Now Imminent?

Adaptimmune Therapeutics plc Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Adaptimmune Therapeutics plc Completes Submission of Rolling Biologics License Application to U.S. FDA for Afami-Cel for the Treatment of Advanced Synovial Sarcoma

Consensus estimates of losses per share improve by 26%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Adaptimmune Therapeutics plc to Report Q3, 2023 Results on Nov 08, 2023

Adaptimmune Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its American Depositary Shares

Price target decreased by 24% to US$3.77

Consensus EPS estimates upgraded to US$0.45 loss, revenue downgraded

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Adaptimmune Therapeutics plc to Report Q2, 2023 Results on Aug 09, 2023